Novel mechanisms and therapeutic options in diabetic nephropathy

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 4, 2009, Pages 261-264

  Miyata, Toshio ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced glycation; Hypoxia; Megsin; Oxidative stress; Plasminogen activator inhibitor 1 (PAI 1)

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN RECEPTOR ANTAGONIST; HYPOXIA INDUCIBLE FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; R 147176; UNCLASSIFIED DRUG;

ARTICLE; BLOOD PRESSURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG INHIBITION; GLYCATION; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOXIA; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RENAL PROTECTION;

EID: 67149086950     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.676     Document Type: Article

References (25)

1. Nicholas SB, Aguiniga E, Ren V, et al. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int. 2005; 68:1297-1307.
2. Ma LJ, Mao SL, Taylor KL, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes. 2004; 53: 336-346.
3. Izuhara Y, Takahashi S, Nangaku M, et al. Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on anti-coagulation and anti-fibrosis. Arterioscler Thromb Vase Biol. 2008; 28:672-677.
4. Huang Y, Haraguchi M, Lawrence DA, et al. A mutant, noninhibito-ry plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest. 2003; 112: 379-388.
5. Miyata T, Nangaku M, Suzuki D, et al. A mesangium-predominant gene, megsin, is a new serpin upregulated in IgA nephropathy. J Clin Invest. 1998,102: 828-836.
6. Suzuki D, Miyata T, Nangaku M, et al. Expression of megsin mRNA, a novel mesangium-predominant gene, in the renal tissues of various glomerular diseases. J Am Soc Nephrol. 1999; 10:2606-2613.
7. Miyata T, Inagi R, Nangaku M, et al. Overexpression of the serpin megsin induces progressive mesangial cell proliferation and expansion. J Clin Invest. 2002; 109: 585-593.
8. Inagi R, Yamamoto Y, Nangaku M, et al. A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice. Diabetes. 2006; 55: 356-366.
9. Ohtomo S, Nangaku M, Izuhara, Y, et al. The role of megsin, a serine protease inhibitor, in diabetic mesangial matrix accumulation. Kidney Int. 2008; 74: 768-774.
10. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006; 17: 17-25.
11. Izuhara Y, Nangaku M, Inagi R, et al. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol. 2005; 16: 3631-3641.
12. Ries M, Basseau F, Tyndal B, et al. Renal diffusion and BOLD MRI in experimental diabetic nephropathy. Blood oxygen level-dependent. J Magn Reson Imaging. 2003; 17:104-113.
13. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nature Rev Mol Cell Biol. 2004; 5:343-354.
14. Salnikow K, Donald SP, Bruick RK, et al. Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. J Biol Chem. 2004; 279:40337-40344.
15. Ohtomo S, Nangaku M, Izuhara Y, et al. Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model. Nephrol Dial Transplant. 2007; 23:1166-1172.
16. Nangaku M, Izuhara Y, Takizawa S, et al. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler Thromb Vase Biol. 2007; 27:2548-2554.
17. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005; 353: 782-792.
18. Takeda K, Aguila HL, Parikh NS, et al. Regulation of adult erythropoie-sis by prolyl hydroxylase domain proteins. Blood. 2007; 111: 3229-3235.
19. Takeda K, Cowan A, Fong G-H. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation. 2007; 116: 774-781.
20. Aragonés J, Schneider M, Van Geyte K, et al. Deficiency or inhibition of oxygen sensor Phdl induces hypoxia tolerance by reprogramming basal metabolism. Nature Genet. 2008; 40:170-180.
21. Miyata T, van Ypersele de Strihou C, Ueda Y, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol. 2002; 13:2478-2487.
22. Nangaku M, Miyata T, Sada T, et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol. 2003; 14:1212-1222.
23. Izuhara Y, Sada T, Yanagisawa H, et al. A novel sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats. Arterio Thromb Vas Biol. 2008; 28:1767-1773.
24. Izuhara Y, Nangaku M, Takizawa S, et al. A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models. Nephrol Dial Transplant. 2008; 23:497-509.
25. Takizawa S, Izuhara Y, Kitao Y, et al. A novel inhibitor of advanced glycation and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia. Brain Res. 2007; 1183:124-137.